Navigation Links
Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference

LOS ANGELES--(BUSINESS WIRE)--Apr 16, 2007 - Introgen Therapeutics, Inc. (NASDAQ:INGN) reported updated ADVEXIN(R) biomarker data over the weekend in Los Angeles, California at the Annual Meeting of the American Association for Cancer Research.

Abnormality of the p53 tumor suppressor is one of the most common and fundamental molecular defects in cancer. ADVEXIN's mechanism of action is targeted to restoring p53 tumor suppressor function and the detection of abnormal p53 is a logical predictive biomarker for ADVEXIN efficacy. In a study of 28 recurrent head and neck cancer patients in Phase 2 clinical trials, abnormal p53 was shown to correlate with increased survival and tumor responses following ADVEXIN treatment.

The median survival of patients with tumors expressing the abnormal p53 biomarker was 11.6 months compared to only 3.5 months in patients whose tumors had normal p53. The association between the abnormal p53 biomarker and increased survival following ADVEXIN therapy was highly statistically significant (p=0.0007).

The abnormal p53 biomarker was also associated with a statistically significant increase in tumor responses to ADVEXIN therapy. A reduction in tumor size was observed in 40 percent of patients with the abnormal p53 biomarker compared to none (zero percent) of patients with p53 normal tumors. In addition, tumor growth control lasting for a minimum of two treatment cycles was observed in 75 percent of patients with abnormal p53 tumors compared to 27 percent of patients with a normal p53 biomarker. Both the increased reduction in tumor size and tumor growth control associated with the abnormal p53 biomarker were statistically significant (p=0.02).

Importantly, patients with abnormal p53 tumors are known to have poor responses and survival following standard treatments. These patients have the greatest need for new therapies and they achieved the most benefit from ADVEXIN t
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
2. Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors
3. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
4. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
5. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
8. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
9. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
10. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
11. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Amarin Corporation plc (Nasdaq: AMRN ... the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference ... will be held at the Nikko Hotel in San Francisco. ... be available at the following URL:   ...
... received 510(k) clearance from the U.S. Food and Drug ... spot scanning. Spot scanning is a proton therapy delivery ... the tumor by using thousands of small individual beamlets ... Intensity Modulated Proton Therapy (IMPT). XiO, Elekta,s ...
Cached Medicine Technology:Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference 2Elekta Receives FDA 510(k) Clearance for XiO Software to Plan Spot Scanning for Proton Therapy 2
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... history of snoring, apnea , , WEDNESDAY, June 11 (HealthDay News) ... a sleep-related breathing disorder, says a University of Virginia study. ... to 18 years, who were referred to a pediatric sleep ... an increased frequency of snoring. , The children,s neck size, ...
... been ruled out as source of contaminated tomatoes, they ... health officials said Wednesday they are zeroing in on ... contaminated tomatoes. , "The question is where specifically did ... for foods at the U.S. Food and Drug Administration ...
... Mayo Clinic research suggests unmarried women living in rural ... counterparts. This lower health status often includes greater instances ... study were recently published in the Journal of ... care physicians should take a proactive role in addressing ...
... Case Western Reserve University School of Medicine and Penn ... that reduces sterile inflammation within the cornea. Published in ... Biology, Dr. Eric Pearlman and Dr. Mark Kester ... delivered in nano-sized packages reduces corneal haze, corneal thickening ...
... of some NSAIDS, it could prevent buildup of plaque ... (HealthDay News) -- A class of drugs called gamma-secretase ... study suggests. , A hallmark of Alzheimer,s is so-called ... gamma-secretase modulators reduce the production of long pieces of ...
... Paris, France, Wednesday June 11th 2008: At least 50% ... state free of signs and symptoms) within 36 weeks ... in combination with tight control, according to results of ... Congress of the European League Against Rheumatism in Paris, ...
Cached Medicine News:Health News:Children's Neck Size Associated With Sleep Disorders 2Health News:U.S. Health Officials Closer to Origin of Salmonella Outbreak 2Health News:U.S. Health Officials Closer to Origin of Salmonella Outbreak 3Health News:U.S. Health Officials Closer to Origin of Salmonella Outbreak 4Health News:Mayo Clinic study reveals rural, unmarried women at higher risk for depression 2Health News:New Class of Drugs May Fight Alzheimer's 2Health News:New Class of Drugs May Fight Alzheimer's 3Health News:50 percent of recent onset RA patients become free of signs and symptoms within 36 weeks 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
This unit is the finest standalone handswitch bipolar unit available....
...
...
Medicine Products: